<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63748">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01892137</url>
  </required_header>
  <id_info>
    <org_study_id>LP0041-62</org_study_id>
    <nct_id>NCT01892137</nct_id>
  </id_info>
  <brief_title>Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%</brief_title>
  <official_title>Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <authority>Australia: Human Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this trial is to demonstrate the predictive value of the clinical
      diagnosis of clearance of Actinic Keratoses after treatment with Ingenol Mebutate using
      histopathological examination as the standard.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clearance of AK</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary response criterion is the clinical and histological clearance of AK at Day 57. Clinical Clearance will be measured by counting AKs, and histological clearance will be by performing a biopsy (result reported as AK or not AK).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete clearance of AKs in the Selected Treatment Area</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Efficacy in terms of complete clearance of AKs in the STA and histological clearance of pre-identified lesion.  AK clearance will be determined by AK count. Clearance of the pre-identified lesion will be assessed by a histopatholgist from a biopsy sample and reported as AK or not AK.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>Open label active</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ingenol mebutate gel 0.05%</intervention_name>
    <description>Once daily for 2 consecutive days</description>
    <arm_group_label>Open label active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be male or female and at least 18 years of age.

          -  Female patients must be on non-childbearing potential or if of childbearing
             potential then negative serum and urine pregnancy test and using effective
             contraception

          -  Ability to provide informed consent

          -  Subjects must have 5-9 clinically typical, visible and discrete AK lesions within a
             contiguous 25cm2 treatment area on the trunk and extremities except the back of the
             hand

          -  AK should be confirmed by histopathology of one of the AK's prior to inclusion

        Exclusion Criteria:

          -  location of the selected treatment area within 5cm of an incompletely healed wound or
             within 10cm of a suspected basal cell carcinoma or squamous cell carcinoma

          -  undergone Cosmetic or therapeutic procedures

          -  use of acid-containing therapeutic products within 2cm of the selected treatment area
             in the 2 weeks prior to Visit 1

          -  use of topical creams/lotions, artificial tanners or topical steroids within 2cm of
             the selected treatment areas in the 2 weeks prior to visit 1.

          -  treatment with immunomodulators, or interferon/interferon inducers or systemic
             medications that suppress the immune system within 4 weeks of visit 1

          -  treatment with 5-FU, imiquimod, diclofenac, ingenol mebutate of photodynamic therapy
             within 2cm of the treatment area in the 8 weeks prior to visit 1

          -  use of systemic retinoids

          -  those who are currently participating in any other interventional clinical trial

          -  females who are pregnant or are breastfeeding

          -  those known or suspected of not being able to comply with the requirements of the
             protocol or provide consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martina Ulrich</last_name>
    <role>Principal Investigator</role>
    <affiliation>Collegium Medicum Berlin GmbH, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southderm Pty Ltd</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melanoma Institute Australia</name>
      <address>
        <city>north Sydney</city>
        <state>New South Wales</state>
        <zip>2060</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Skin Centre</name>
      <address>
        <city>Benowa</city>
        <state>Queensland</state>
        <zip>4217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South East Dermatology Centre</name>
      <address>
        <city>Carina Heights</city>
        <state>Queensland</state>
        <zip>4152</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St John of God Dermatology</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burswood Dermatology</name>
      <address>
        <city>Victoria Park</city>
        <state>Western Australia</state>
        <zip>6100</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Dermatologie &amp; Allergologie Klinikum Augsburg Süd</name>
      <address>
        <city>Augsburg</city>
        <zip>86179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collegium Medicum Berlin GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Zentrum Bonn Friedensplatz</name>
      <address>
        <city>Bonn</city>
        <zip>42275</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautarztpraxis Prof. Dr. med. C. Termeer</name>
      <address>
        <city>Stuttgart</city>
        <zip>70499</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.leopharma.com</url>
    <description>LEO Pharma</description>
  </link>
  <link>
    <url>http://www.tga.gov.au</url>
    <description>Therapeutic Goods Administration</description>
  </link>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 29, 2014</lastchanged_date>
  <firstreceived_date>June 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Actinic Keratosis</keyword>
  <keyword>Histopathology</keyword>
  <keyword>Reflectance Confocal Microscopy</keyword>
  <keyword>Local Skin Reaction</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
